Oxford BioDynamics - OBD Share Forecast, Price & News

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

Analyst Upgrades and Downgrades

Separately, Shore Capital reiterated a "house stock" rating on shares of Oxford BioDynamics in a research report on Tuesday, June 28th.

Oxford BioDynamics Price Performance

LON:OBD opened at GBX 13.25 ($0.16) on Friday. The business's fifty day moving average is GBX 14.63 and its 200 day moving average is GBX 19.35. Oxford BioDynamics has a fifty-two week low of GBX 11.25 ($0.14) and a fifty-two week high of GBX 54 ($0.65). The company has a market capitalization of £13.30 million and a PE ratio of -1.84. The company has a debt-to-equity ratio of 99.34, a quick ratio of 2.80 and a current ratio of 2.98.

Insider Activity

In other Oxford BioDynamics news, insider Matthew Wakefield acquired 25,000 shares of the stock in a transaction dated Friday, May 20th. The shares were acquired at an average cost of GBX 17 ($0.21) per share, for a total transaction of £4,250 ($5,135.33).